Link-Age

Linkage Pharma is a clinical-stage biotechnology company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology and metabolic diseases. The company's lead candidate, LX-039, is a potent, selective estrogen receptor degrader (SERD) currently being evaluated in Phase 1/2 clinical trials for the treatment of ER-positive, HER2-negative advanced breast cancer. Linkage Pharma is also advancing LX-086, a selective PI3K alpha inhibitor, and LX-132, a CDK4/6 inhibitor, as part of its strategy to develop combination therapies for resistant cancers. By leveraging its expertise in structure-based drug design, the company aims to address significant unmet medical needs in the global oncology market.